Literature DB >> 9502078

Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

H Allgayer1, R Babic, K U Grützner, B C Beyer, A Tarabichi, F W Schildberg, M M Heiss.   

Abstract

Expression of proteolytic parameters of the urokinase-type plasminogen activator (uPA) system [uPA receptor (uPA-R), plasminogen activator inhibitor (PAI)-1] has been proven to be an independent prognostic parameter in cancer. However, it has not been considered that the uPA system is interacting with several other protease/inhibitor systems, neither has a comparable prognostic role of these factors been investigated. Moreover, studies evaluating specific protease patterns indicating high individual risk are missing completely. Therefore, in a consecutive prospective series of 203 gastric cancer patients, the expression of activators (plasminogen, tPA, MMP-2, cathepsin D, antithrombin 3) and inhibitors (alpha-2-antiplasmin, alpha-2-macroglobulin, alpha-1-antitrypsin, alpha-1-antichymotrypsin) of proteolysis was studied immunohistochemically in the tumor epithelium semiquantitatively (score 0-3) in addition to the uPA system. Kaplan-Meier analysis (median time of follow-up 31 months) revealed a significant association of cathepsin D (P=0.0042), alpha-2-macroglobulin (P=0.0281) and antitrypsin (P=0.0372) with disease-free survival and of cathepsin D (P=0.0018), antitrypsin (P=0.0112) and antichymotrypsin (P=0.0002) with overall survival. Multivariate Cox analysis performed to correct these results for relative impact of the uPA system and established prognostic factors showed PAI-1 (disease-free survival: P=0.002, relative risk 1.86; overall survival: P=0.005, relative risk 1.39), pT and pN as independent parameters. Cathepsin D was shown to have an independent impact on disease-free survival (P=0.020, relative risk 2.98). Comparative chi-square analysis of cases with poor and good prognoses revealed that in patients with good clinical outcome, inhibitors of proteolysis are correlated significantly, whereas in patients with poor prognosis activators of proteolysis are significantly associated preferentially and significant correlations with the uPA-R are dominant. For detailed pattern analysis, stepwise overall Kaplan-Meier analyses were performed in subgroups of high uPA-R-, uPA-, PAI1- and cathepsin D expression for two additional proteases each. From these analyses, the combination of high (score 2/3) expression of uPA-R, PAI-1, antichymotrypsin and alpha-2-macroglobulin was identified as a high-risk pattern, representing parameters known to be essential for uPA-R internalization and recycling. This suggests some of the uPA-associated proteases and inhibitors investigated as univariate prognostic parameters in gastric cancer. Cathepsin D is a new independent parameter for disease-free survival. The study further demonstrates that a protease pattern promoting uPA-R recycling in tumor cells especially indicates high individual risk tumors in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502078     DOI: 10.1023/a:1006564002679

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  39 in total

1.  Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.

Authors:  W Hollas; F Blasi; D Boyd
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

2.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

Review 3.  Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.

Authors:  F Blasi
Journal:  Bioessays       Date:  1993-02       Impact factor: 4.345

4.  Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.

Authors:  L Goretzki; M Schmitt; K Mann; J Calvete; N Chucholowski; M Kramer; W A Günzler; F Jänicke; H Graeff
Journal:  FEBS Lett       Date:  1992-02-03       Impact factor: 4.124

Review 5.  Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.

Authors:  P A Andreasen; L Sottrup-Jensen; L Kjøller; A Nykjaer; S K Moestrup; C M Petersen; J Gliemann
Journal:  FEBS Lett       Date:  1994-02-07       Impact factor: 4.124

Review 6.  Structure and function of the urokinase receptor.

Authors:  L B Møller
Journal:  Blood Coagul Fibrinolysis       Date:  1993-04       Impact factor: 1.276

7.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.

Authors:  H Pedersen; J Grøndahl-Hansen; D Francis; K Osterlind; H H Hansen; K Danø; N Brünner
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

8.  Tumor-associated alpha-2-macroglobulin in human melanomas.

Authors:  J Matoŝka; T Wahlström; A Vaheri; J Bízik; M Grófová
Journal:  Int J Cancer       Date:  1988-03-15       Impact factor: 7.396

9.  alpha2-Macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver.

Authors:  S M Smorenburg; P Griffini; A B Tiggelman; A F Moorman; W Boers; J F Van Noorden
Journal:  Hepatology       Date:  1996-03       Impact factor: 17.425

10.  Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane.

Authors:  W F Grigioni; A D'Errico; C Fortunato; M Fiorentino; A M Mancini; W G Stetler-Stevenson; M E Sobel; L A Liotta; M Onisto; S Garbisa
Journal:  Mod Pathol       Date:  1994-02       Impact factor: 7.842

View more
  17 in total

1.  S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs.

Authors:  Christina L Grek; Danyelle M Townsend; Joachim D Uys; Yefim Manevich; Woodrow J Coker; Christopher J Pazoles; Kenneth D Tew
Journal:  Cancer Res       Date:  2012-03-08       Impact factor: 12.701

2.  Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma.

Authors:  Nicolas Tsavaris; Christos Kosmas; Petros Kopterides; Dimitrios Tsikalakis; Hlias Skopelitis; Fotini Sakelaridi; Nikitas Papadoniou; Michalis Tzivras; Vasilios Balatsos; Christos Koufos; Athanasios Archimandritis
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

3.  Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.

Authors:  Li Zhang; Zhong-Sheng Zhao; Guo-Qing Ru; Jie Ma
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

4.  MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.

Authors:  J Mrena; J-P Wiksten; S Nordling; A Kokkola; A Ristimäki; C Haglund
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

5.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

6.  Analysis of gene expression profile of pancreatic carcinoma using cDNA microarray.

Authors:  Zhi-Jun Tan; Xian-Gui Hu; Gui-Song Cao; Yan Tang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

7.  Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.

Authors:  Feng Ji; Yue-Liang Chen; En-Yun Jin; Wei-Lin Wang; Zi-Li Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

Review 8.  Recent advances in the molecular diagnostics of gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

9.  Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas.

Authors:  Jan Dimberg; Karin Ström; Sture Löfgren; Niklas Zar; Anders Hugander; Andreas Matussek
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

10.  Protease inhibitor SERPINA1 expression in epithelial ovarian cancer.

Authors:  Karine Normandin; Benjamin Péant; Cécile Le Page; Manon de Ladurantaye; Véronique Ouellet; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Clin Exp Metastasis       Date:  2010-01-05       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.